{"filing":{"accession_number":"0001453687-26-000100","cik":"0001453687","ticker":"RNAC","company_name":"Cartesian Therapeutics, Inc.","form":"8-K","filing_date":"2026-08-06","report_date":"2026-08-06","primary_document":"rnac-20260806.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1453687/000145368726000100/rnac-20260806.htm"},"events":[{"id":25757,"run_id":23377,"accession_number":"0001453687-26-000100","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"summary":"Cartesian Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (R\u0026D expenses of $20.4M, G\u0026A expenses of $8.7M, net income of $15.8M), cash position ($149.3M), and operational updates on clinical trials and partnerships. This is a standard quarterly earnings release under Item 2.02.","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-08-06","form":"8-K","submitted_at":null,"items":[{"id":26669,"accession_number":"0001453687-26-000100","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cartesian Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (R\u0026D expenses of $20.4M, G\u0026A expenses of $8.7M, net income of $15.8M), cash position ($149.3M), and operational updates on clinical trials and partnerships. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:34.801562+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":26669,"accession_number":"0001453687-26-000100","item_number":"2.02","item_title":"Results of Operations and Financial Condition.","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Cartesian Therapeutics announced its financial results for the quarter ended June 30, 2026, via press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (R\u0026D expenses of $20.4M, G\u0026A expenses of $8.7M, net income of $15.8M), cash position ($149.3M), and operational updates on clinical trials and partnerships. This is a standard quarterly earnings release under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-09T02:31:34.801562+00:00","company_name":"Cartesian Therapeutics, Inc.","ticker":"RNAC","filing_date":"2026-08-06"}]}